Sageworth Trust CO Bei Gene, Ltd. Transaction History

Sageworth Trust CO

$2.11 Billion
Q3 2025

A detailed history of Sageworth Trust CO transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Sageworth Trust CO holds 3,596 shares of BGNE stock, worth $815,249. This represents 0.04% of its overall portfolio holdings.

Number of Shares

3,596

Holding current value

$815,249

% of portfolio

0.04%

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2025 Nov 07, 2025	BUY	N/A	3,596 New	3,596 $815,000
Q1 2023 May 08, 2023	BUY	$215.53 - $274.5 $5,172 - $6,588	24 New	24 $5,000

Others Institutions Holding BGNE

# of Institutions

297

Shares Held

30.4M

Call Options Held

147K

Put Options Held

195K

Baker Bros. Advisors LP New York, NY

8.8M
Shares

$1.99 Billion
16.25% of portfolio
Primecap Management CO Pasadena, CA

5.08M
Shares

$1.15 Billion
0.91% of portfolio
Capital International Investors Los Angeles, CA

5.05M
Shares

$1.14 Billion
0.19% of portfolio
Price T Rowe Associates Inc Baltimore, MD

1.63M
Shares

$370 Million
0.06% of portfolio
Hhlr Advisors, Ltd. Grand Cayman, E9

1.03M
Shares

$234 Million
7.05% of portfolio

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sageworth Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on Sageworth Trust CO with notifications on news.

Account